Global EditionASIA 中文雙語Fran?ais
    World
    Home / World / Americas

    US: AstraZeneca results may have included outdated info

    Updated: 2021-03-24 04:06
    Share
    Share - WeChat
    [Photo/Agencies]

    WASHINGTON — AstraZeneca may have included “outdated information” in touting the effectiveness of its COVID-19 vaccine in a U.S. study, federal health officials said Tuesday in an unusual public rift that could further erode confidence in the shot.

    In response, AstraZeneca said that it is working on more up-to-date information and that the more recent findings are consistent with the earlier ones. It promised an update within 48 hours.

    It was not clear exactly what concerns U.S. health officials have. But the unprecedented tension erupted just hours after AstraZeneca released information it hoped would help settle lingering questions about the effectiveness of a vaccine that is being widely used in Europe and other parts of the world and is about to be considered for use in the U.S.

    The company announced on Monday that a predominantly U.S. study of 32,000 volunteers showed its vaccine was 79% effective in preventing symptomatic COVID-19 disease. It also stressed there were no severe illnesses or hospitalizations among volunteers given the vaccine, compared with five cases among those given dummy shots.

    But shortly after midnight, the National Institutes of Health issued a statement saying the independent monitors that oversee the study had “expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data.” The NIH urged the company to “ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.” Outside experts were surprised and puzzled by the spat. But they noted that ultimately the Food and Drug Administration will scrutinize all the data before deciding whether AstraZeneca's vaccine can be rolled out in the U.S. “It would seem that whatever this communication misstep is, at the end of the day the data will have to stand for itself,” said Dr. Jesse Goodman of Georgetown University, a former FDA vaccine chief.

    The NIH's Dr. Anthony Fauci told ABC's “Good Morning America” that the incident “really is what you call an unforced error" and that he expects the discrepancy to be straightened out.

    Fauci also said the episode shows the U.S. regulatory system is working: “The data and safety monitoring board picking up this discrepancy was an example of a safeguard.” But that nitty-gritty seldom is seen by the public, something now exposed by the extraordinary microscope being applied to development of the world's COVID-19 vaccines.

    Every vaccine trial is overseen by a “data and safety monitoring board,” or DSMB. These boards include scientists and statisticians who are experts in their fields but have no ties to either the government or the vaccine makers.

    In the AstraZeneca study, just like studies of the other vaccines in use, some participants get the real vaccine and the rest get dummy shots, and neither they nor their doctors know which is which. Only the DSMB has the power to unlock the code of who got which and peek at how the volunteers are faring before a study is finished.

    The DSMB watches for safety concerns and also deems when the study has met pre-determined endpoints showing it's time for an effectiveness calculation. It was the NIH-appointed DSMB that raised the concerns about AstraZeneca's data.

    On Tuesday, AstraZeneca said that the data it first released included COVID-19 cases that occurred up to Feb. 17, as the study rules specified, and that it is continuing to analyze cases that have occurred since then. It said a preliminary analysis of more recent data was consistent with what it had already reported.

    It is common for companies developing COVID-19 vaccines to release early data and to continue studying results as they come in. Some experts had hoped that Monday's AstraZeneca announcement would help rebuild public confidence in the shot around the world.

    The vaccine is used widely in Britain, across the European continent and in other countries, but its rollout was troubled by inconsistent study reports about its effectiveness, and then last week a scare about blood clots that had some countries temporarily pausing inoculations.

    The U.S. study findings announced by AstraZeneca were consistent with studies from elsewhere — and real-world use in Britain — that found the vaccine offers good protection against the worst COVID-19 has to offer. But company executives refused repeated requests from reporters to provide a breakdown of the 141 COVID-19 cases it was using to make the case for the shot's effectiveness.

    The company has said it aims to file an application with the FDA in the coming weeks.

    Agencies via Xinhua

    Most Viewed in 24 Hours
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    亚洲色无码专区在线观看| 欧美日韩中文字幕| 亚洲国产综合精品中文字幕| 波多野结AV衣东京热无码专区| 亚洲AV无码无限在线观看不卡| 日韩一本之道一区中文字幕| 人妻中文字幕无码专区| 免费无码国产欧美久久18| 中文字幕在线视频播放| 在线看福利中文影院| 丰满人妻AV无码一区二区三区| 日韩乱码人妻无码中文字幕久久| 熟妇人妻系列aⅴ无码专区友真希| 少妇人妻88久久中文字幕| 少妇中文无码高清| 精品国精品无码自拍自在线| 亚洲AV无码一区二区乱孑伦AS| 亚洲欧美精品综合中文字幕 | 亚洲色无码专区在线观看| 合区精品久久久中文字幕一区| 色综合网天天综合色中文男男| 大地资源中文在线观看免费版| 伊人久久无码精品中文字幕| 高清无码在线视频| 国产午夜无码片免费| 精品无码国产自产拍在线观看蜜| 久久av无码专区亚洲av桃花岛| 日韩免费无码一区二区三区 | 精品久久久久久无码国产| 日韩精品无码一区二区三区免费 | 精品国产一区二区三区无码| 日韩免费无码视频一区二区三区| 无码一区二区三区在线观看 | 92午夜少妇极品福利无码电影| 久久久久久亚洲AV无码专区| YY111111少妇无码理论片| 国产羞羞的视频在线观看 国产一级无码视频在线 | 无码一区二区三区在线观看| 人妻夜夜添夜夜无码AV| 成在人线AV无码免观看麻豆| 亚洲国产精品无码久久青草|